X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9) 9
female (8) 8
male (7) 7
middle aged (7) 7
aged (6) 6
adult (5) 5
aged, 80 and over (5) 5
index medicus (5) 5
oncology (5) 5
recurrence (4) 4
cancer (3) 3
dexamethasone - administration & dosage (3) 3
drug administration schedule (3) 3
multiple myeloma - drug therapy (3) 3
oligopeptides - administration & dosage (3) 3
oligopeptides - adverse effects (3) 3
research (3) 3
risk factors (3) 3
survival (3) 3
tumors (3) 3
abridged index medicus (2) 2
analysis (2) 2
animals (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
article (2) 2
bortezomib (2) 2
breast cancer (2) 2
breast neoplasms - mortality (2) 2
care (2) 2
chemotherapy (2) 2
clinical trials (2) 2
cohort studies (2) 2
drug therapy (2) 2
health aspects (2) 2
hif2-alpha (2) 2
kidney cancer (2) 2
maximum tolerated dose (2) 2
mutation (2) 2
neoplasms - drug therapy (2) 2
oligopeptides - pharmacokinetics (2) 2
original reports (2) 2
pas-b domain (2) 2
predictors (2) 2
prevention (2) 2
public, environmental & occupational health (2) 2
quality of life (2) 2
race (2) 2
seer program (2) 2
thalidomide - administration & dosage (2) 2
thalidomide - analogs & derivatives (2) 2
transcription factor (2) 2
treatment outcome (2) 2
adjuvant endocrine therapy (1) 1
adolescent (1) 1
advanced colorectal-cancer (1) 1
african americans - statistics & numerical data (1) 1
age distribution (1) 1
american (1) 1
and end results (1) 1
angiogenesis (1) 1
antagonist drugs (1) 1
antibodies, monoclonal - pharmacokinetics (1) 1
antibodies, monoclonal - pharmacology (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antimitotic agents - adverse effects (1) 1
antimitotic agents - therapeutic use (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - pharmacokinetics (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antitubulin resistance (1) 1
apoptosis (1) 1
area socioeconomic patterns (1) 1
arm (1) 1
arnt (1) 1
aryl hydrocarbon receptor nuclear translocator - genetics (1) 1
aryl hydrocarbon receptor nuclear translocator - metabolism (1) 1
asian (1) 1
asian american (1) 1
asian americans (1) 1
asian americans - statistics & numerical data (1) 1
attitude of health personnel - ethnology (1) 1
basic helix-loop-helix transcription factors - antagonists & inhibitors (1) 1
basic helix-loop-helix transcription factors - genetics (1) 1
basic helix-loop-helix transcription factors - metabolism (1) 1
binding sites (1) 1
biomarkers, tumor - metabolism (1) 1
breast (1) 1
breast cancer-specific mortality (1) 1
breast carcinoma (1) 1
breast neoplasms - ethnology (1) 1
breast neoplasms - metabolism (1) 1
cancer therapies (1) 1
carcinoma, ductal, breast - metabolism (1) 1
carcinoma, ductal, breast - mortality (1) 1
carcinoma, renal cell (1) 1
carcinoma, renal cell - drug therapy (1) 1
carcinoma, renal cell - genetics (1) 1
carcinoma, renal cell - metabolism (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 2, pp. 142 - 152
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. 2508 - 2508
Journal Article
Nature, ISSN 0028-0836, 2016, Volume 539, Issue 7627, pp. 112 - 117
Clear cell renal cell carcinoma (ccRCC) is characterized by inactivation of the von Hippel-Lindau tumour suppressor gene (VHL)(1,2). Because no other gene is... 
HIF-2-ALPHA | INHIBITION | RNA | GENE | PAS-B DOMAIN | DNA | MULTIDISCIPLINARY SCIENCES | HIF2-ALPHA | HYPOXIA-INDUCIBLE FACTOR-2 | TRANSCRIPTION FACTOR | EXPRESSION | Sulfones - therapeutic use | Kidney Neoplasms - genetics | Humans | Gene Expression Regulation, Neoplastic | Carcinoma, Renal Cell - genetics | Male | Kidney Neoplasms - metabolism | Aryl Hydrocarbon Receptor Nuclear Translocator - metabolism | Molecular Targeted Therapy | Sulfones - pharmacology | Indans - therapeutic use | Erythropoietin - blood | Sunitinib | Basic Helix-Loop-Helix Transcription Factors - metabolism | Female | Indoles - pharmacology | Indans - administration & dosage | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Binding Sites | Reproducibility of Results | Basic Helix-Loop-Helix Transcription Factors - genetics | Carcinoma, Renal Cell - pathology | Basic Helix-Loop-Helix Transcription Factors - antagonists & inhibitors | Mice, SCID | Xenograft Model Antitumor Assays | Carcinoma, Renal Cell - metabolism | Pyrroles - pharmacology | Animals | Cell Transformation, Neoplastic | Cell Line, Tumor | Erythropoietin - antagonists & inhibitors | Indoles - therapeutic use | Kidney Neoplasms - pathology | Mice, Inbred NOD | Aryl Hydrocarbon Receptor Nuclear Translocator - genetics | Mice | Mutation | Kidney Neoplasms - drug therapy | Drug Resistance, Neoplasm - drug effects | Indans - pharmacology | Sulfones - administration & dosage | Physiological aspects | Molecular targeted therapy | Transcription factors | Carcinoma, Renal cell | Methods | kidney cancer | HIF-1β (F446L) | RCC | patient-derived xenograft | EPAS1 | HIF-2α (G323E) | renal cancer | ARNT
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 03/2018, Volume 36, Issue 9, pp. 867 - 867
Purpose The von Hippel-Lindau tumor suppressor is inactivated in the majority of clear cell renal cell carcinomas (ccRCCs), leading to inappropriate... 
HIF2-ALPHA | ONCOLOGY | PAS-B DOMAIN | TRANSCRIPTION FACTOR | CANCER | TUMORS | ORIGINAL REPORTS
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2015, Volume 33, Issue 7, pp. 732 - 739
Journal Article
Journal Article
Social Science & Medicine, ISSN 0277-9536, 2006, Volume 62, Issue 2, pp. 337 - 347
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 21, pp. 4036 - 4036
Abstract Abstract 4036 Background: Carfilzomib, a next-generation proteasome inhibitor, has shown a favorable efficacy and safety profile in phase 1 and 2... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. 2506 - 2506
Journal Article
Nature, ISSN 0028-0836, 11/2016, Volume 539, Issue 7627, p. 112
Clear cell renal cell carcinoma (ccRCC) is characterized by inactivation of the von Hippel-Lindau tumour suppressor gene (VHL)1,2. Because no other gene is... 
Angiogenesis | Antagonist drugs | Kidney cancer | Clinical trials | Tumorigenesis | Mutation | Gene expression | Vascular endothelial growth factor | Cancer therapies | Tumors
Journal Article
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 79 - 79
Abstract Background: Lenalidomide with dexamethasone (Rd) is a standard of care used for pts with relapsed multiple myeloma (RMM). The randomized, open-label,... 
Journal Article
20.